(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.12%.
Praxis Precision Medicines's earnings in 2025 is -$273,036,000.On average, 17 Wall Street analysts forecast PRAX's earnings for 2025 to be -$332,765,423, with the lowest PRAX earnings forecast at -$350,205,424, and the highest PRAX earnings forecast at -$314,302,629. On average, 17 Wall Street analysts forecast PRAX's earnings for 2026 to be -$330,417,250, with the lowest PRAX earnings forecast at -$505,089,838, and the highest PRAX earnings forecast at -$147,829,891.
In 2027, PRAX is forecast to generate -$250,634,371 in earnings, with the lowest earnings forecast at -$423,726,507 and the highest earnings forecast at -$26,257,530.